<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD00820000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P11712</UniProt_ID>
  <Seq_Length>490</Seq_Length>
  <Molecule_Weight>55628</Molecule_Weight>
  <KEGG_ID>hsa:1559</KEGG_ID>
  <Orthology_ID>K17719</Orthology_ID>
  <Function_Summary>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan.</Function_Summary>
  <Catalytic_Mechanism>(+)-(R)-limonene + NADPH + O(2) = (+)-trans-carveol + NADP(+) + H(2)O.@@(-)-(S)-limonene + NADPH + O(2) = (-)-trans-carveol + NADP(+) + H(2)O.@@(-)-(S)-limonene + NADPH + O(2) = (-)-perillyl alcohol + NADP(+) + H(2)O.</Catalytic_Mechanism>
  <Pfam_ID>PF00067:p450</Pfam_ID>
  <Allosteric_Activator_Count>1</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>(R)-limonene 6-monooxygenase</Alias>
      <Alias>Cytochrome P450 PB-1</Alias>
      <Alias>(S)-limonene 6-monooxygenase</Alias>
      <Alias>Cytochrome P450 MP-8</Alias>
      <Alias>Cytochrome P-450MP</Alias>
      <Alias>CYPIIC9</Alias>
      <Alias>(S)-limonene 7-monooxygenase</Alias>
      <Alias>S-mephenytoin 4-hydroxylase</Alias>
      <Alias>Cytochrome P450 MP-4</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a drug, any naturally occurring or synthetic substance, other than a nutrient, that, when administered or applied to an organism, affects the structure or functioning of the organism; in particular, any such substance used in the diagnosis, prevention, or treatment of disease.</Detail>
      <Keyword>Drug binding</Keyword>
      <Ontology_ID>GO:0008144</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: caffeine + O2 + 2 H+ + 2 e- = 1,3,7-trimethyluric acid + H2O.</Detail>
      <Keyword>Caffeine oxidase activity</Keyword>
      <Ontology_ID>GO:0034875</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the incorporation of one atom from molecular oxygen into a compound and the reduction of the other atom of oxygen to water.</Detail>
      <Keyword>Monooxygenase activity</Keyword>
      <Ontology_ID>GO:0004497</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with heme, any compound of iron complexed in a porphyrin (tetrapyrrole) ring.</Detail>
      <Keyword>Heme binding</Keyword>
      <Ontology_ID>GO:0020037</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: (4S)-limonene + H(+) + NADPH + O(2) = (4S)-perillyl alcohol + H(2)O + NADP(+).</Detail>
      <Keyword>(S)-limonene 7-monooxygenase activity</Keyword>
      <Ontology_ID>GO:0018676</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the formation of a hydroxyl group on a steroid by incorporation of oxygen from O2.</Detail>
      <Keyword>Steroid hydroxylase activity</Keyword>
      <Ontology_ID>GO:0008395</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Any molecular entity that serves as an electron acceptor and electron donor in an electron transport system.</Detail>
      <Keyword>Electron carrier activity</Keyword>
      <Ontology_ID>GO:0009055</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: (-)-limonene + NADPH + H+ + O2 = (-)-trans-carveol + NADP+ + H2O.</Detail>
      <Keyword>(S)-limonene 6-monooxygenase activity</Keyword>
      <Ontology_ID>GO:0018675</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>19</Position>
      <Original>Leu</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>359</Position>
      <Original>Ile</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>144</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>272</Position>
      <Original>Glu</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>150</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>359</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>335</Position>
      <Original>Arg</Original>
      <Variation>Trp</Variation>
    </Muntion>
    <Muntion>
      <Position>417</Position>
      <Original>Gly</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>489</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>358</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>251</Position>
      <Original>His</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>360</Position>
      <Original>Asp</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>413</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The process of removing one or more methyl groups from a molecule, involving the oxidation (i.e. electron loss) of one or more atoms in the substrate.</Detail>
      <Keyword>Oxidative demethylation</Keyword>
      <Ontology_ID>GO:0070989</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving steroids, compounds with a 1,2,cyclopentanoperhydrophenanthrene nucleus.</Detail>
      <Keyword>Steroid metabolic process</Keyword>
      <Ontology_ID>GO:0008202</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A metabolic process that results in the removal or addition of one or more electrons to or from a substance, with or without the concomitant removal or addition of a proton or protons.</Detail>
      <Keyword>Oxidation-reduction process</Keyword>
      <Ontology_ID>GO:0055114</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving monoterpenoid compounds, terpenoids having a C10 skeleton.</Detail>
      <Keyword>Monoterpenoid metabolic process</Keyword>
      <Ontology_ID>GO:0016098</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving urea, the water soluble compound O=C-(NH2)2.</Detail>
      <Keyword>Urea metabolic process</Keyword>
      <Ontology_ID>GO:0019627</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving monocarboxylic acids, any organic acid containing one carboxyl (COOH) group or anion (COO-).</Detail>
      <Keyword>Monocarboxylic acid metabolic process</Keyword>
      <Ontology_ID>GO:0032787</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways resulting in the breakdown of a drug that has originated externally to the cell or organism.</Detail>
      <Keyword>Exogenous drug catabolic process</Keyword>
      <Ontology_ID>GO:0042738</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving a xenobiotic compound, a compound foreign to living organisms. Used of chemical compounds, e.g. a xenobiotic chemical, such as a pesticide.</Detail>
      <Keyword>Xenobiotic metabolic process</Keyword>
      <Ontology_ID>GO:0006805</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <Molecule_Seq>
    <Protein_Seq>MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKVYGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKWKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICSIIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFMKSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTETTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYIDLLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFKKSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVPPFYQLCFIPV</Protein_Seq>
    <DNA_Seq>CTTGTGGTCCTTGTGCTCTGTCTCTCATGTTTGCTTCTCCTTTCACTCTGGAGACAGAGCTCTGGGAGAGGAAAACTCCCTCCTGGCCCCACTCCTCTCCCAGTGATTGGAAATATCCTACAGATAGGTATTAAGGACATCAGCAAATCCTTAACCAATCTCTCAAAGGTCTATGGCCCGGTGTTCACTCTGTATTTTGGCCTGAAACCCATAGTGGTGCTGCATGGATATGAAGCAGTGAAGGAAGCCCTGATTGATCTTGGAGAGGAGTTTTCTGGAAGAGGCATTTTCCCACTGGCTGAAAGAGCTAACAGAGGATTTGGAATTGTTTTCAGCAATGGAAAGAAATGGAAGGAGATCCGGCGTTTCTCCCTCATGACGCTGCGGAATTTTGGGATGGGGAAGAGGAGCATTGAGGACCGTGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAAGGCCTCACCCTGTGATCCCACTTTCATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCCATTATTTTCCATAAACGTTTTGATTATAAAGATCAGCAATTTCTTAACTTAATGGAAAAGTTGAATGAAAACATCAAGATTTTGAGCAGCCCCTGGATCCAGATCTGCAATAATTTTTCTCCTATCATTGATTACTTCCCGGGAACTCACAACAAATTACTTAAAAACGTTGCTTTTATGAAAAGTTATATTTTGGAAAAAGTAAAAGAACACCAAGAATCAATGGACATGAACAACCCTCAGGACTTTATTGATTGCTTCCTGATGAAAATGGAGAAGGAAAAGCACAACCAACCATCTGAATTTACTATTGAAAGCTTGGAAAACACTGCAGTTGACTTGTTTGGAGCTGGGACAGAGACGACAAGCACAACCCTGAGATATGCTCTCCTTCTCCTGCTGAAGCACCCAGAGGTCACAGCTAAAGTCCAGGAAGAGATTGAACGTGTGATTGGCAGAAACCGGAGCCCCTGCATGCAAGACAGGAGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGAGATACATTGACCTTCTCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACATTAAATTCAGAAACTATCTCATTCCCAAGGGCACAACCATATTAATTTCCCTGACTTCTGTGCTACATGACAACAAAGAATTTCCCAACCCAGAGATGTTTGACCCTCATCACTTTCTGGATGAAGGTGGCAATTTTAAGAAAAGTAAATACTTCATGCCTTTCTCAGCAGGAAAACGGATTTGTGTGGGAGAAGCCCTGGCCGGCATGGAGCTGTTTTTATTCCTGACCTCCATTTTACAGAACTTTAACCTGAAATCTCTGGTTGACCCAAAGAACCTTGACACCACTCCAGTTGTCAATGGATTTGCCTCTGTGCCGCCCTTCTACCAGCTGTGCTTCATTCCTGTCTGAAGAAGAGCAGATGGCCTGGCTGCTGCTGTGCAGTCCCTGCAGCTCTCTTTCCTCTGGGGCATTATCCATCTTTGCACTATCTGTAATGCCTTTTCTCACCTGTCATCTCACATTTTCCCTTCCCTGAAGATCTAGTGAACATTCGACCTCCATTACGGAGAGTTTCCTATGTTTCACTGTGCAAATATATCTGCTATTCTCCATACTCTGTAACAGTTGCATTGACTGTCACATAATGCTCATACTTATCTAATGTAGAGTATTAATATGTTATTATTAAATAGAGAAATATGATTTGTGTATTATAATTCAAAGGCATTTCTTTTCTGCATGATCTAAATAAAAAGCATTATTATTTGCTG</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Liver</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Endoplasmic reticulum</CellLocal>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Microsome</CellLocal>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Membrane Associated</CellLocal>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>CYP2C9</Gene_Name>
    <Gene_Alias>CYP2C10</Gene_Alias>
    <Gene_ID>1559</Gene_ID>
    <Genbank_ACCN>NM_000771</Genbank_ACCN>
    <Protein_ACCN>NP_000762</Protein_ACCN>
    <HGNC_ID>2623</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/1559</Gene_URL>
    <UCSC_ID>uc001kka.4</UCSC_ID>
    <EMBL_ID>ENSG00000138109</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Gliclazide Toxicity</Disease_Name>
      <Disease_Detail>Gliclazide Toxicity</Disease_Detail>
      <Disease_DB>GLC082</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gliclazide_toxicity?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Susceptibility to Bleeding Due to Warfarine Treatment</Disease_Name>
      <Disease_Detail>Susceptibility to Bleeding</Disease_Detail>
      <Disease_DB>SSC015</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/susceptibility_to_bleeding_due_to_warfarine_treatment?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Susceptibility to Hypoglycemia Due to Gliclazide Treatment</Disease_Name>
      <Disease_Detail>Susceptibility to Hypoglycemia</Disease_Detail>
      <Disease_DB>SSC008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/susceptibility_to_hypoglycemia_due_to_gliclazide_treatment?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fluindione Toxicity</Disease_Name>
      <Disease_Detail>Fluindione Toxicity</Disease_Detail>
      <Disease_DB>FLN006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fluindione_toxicity?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Multiple Chemical Sensitivity</Disease_Name>
      <Disease_Detail>Multiple Chemical Sensitivity</Disease_Detail>
      <Disease_DB>MLT001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/multiple_chemical_sensitivity?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Acenocoumarol Toxicity</Disease_Name>
      <Disease_Detail>Acenocoumarol Toxicity</Disease_Detail>
      <Disease_DB>ACN025</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/acenocoumarol_toxicity?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Glipizide Toxicity</Disease_Name>
      <Disease_Detail>Glipizide Toxicity</Disease_Detail>
      <Disease_DB>GLP006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/glipizide_toxicity?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Warfarin Resistance</Disease_Name>
      <Disease_Detail>Warfarin Resistance</Disease_Detail>
      <Disease_DB>WRF001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/warfarin_resistance?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Susceptibility to Bleeding Due to Acenocoumarol Treatment</Disease_Name>
      <Disease_Detail>Susceptibility to Bleeding</Disease_Detail>
      <Disease_DB>SSC031</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/susceptibility_to_bleeding_due_to_acenocoumarol_treatment?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Glimepiride Toxicity</Disease_Name>
      <Disease_Detail>Glimepiride Toxicity</Disease_Detail>
      <Disease_DB>GLM042</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/glimepiride_toxicity?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Coumarin Resistance</Disease_Name>
      <Disease_Detail>Coumarin Resistance</Disease_Detail>
      <Disease_DB>CMR002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/coumarin_resistance?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diffuse Alveolar Hemorrhage</Disease_Name>
      <Disease_Detail>Diffuse Alveolar Hemorrhage</Disease_Detail>
      <Disease_DB>DFF031</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diffuse_alveolar_hemorrhage?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Warfarine Dose Selection in the Treatment of Venous Thrombosis and Atrial Fibrillation</Disease_Name>
      <Disease_Detail>Warfarine Dose Selection in the Treatment of Venous Thrombosis and Atrial Fibrillation</Disease_Detail>
      <Disease_DB>WRF005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/warfarine_dose_selection_in_the_treatment_of_venous_thrombosis_and_atrial_fibrillation?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Susceptibility to Bleeding Due to Fluindione Treatment</Disease_Name>
      <Disease_Detail>Susceptibility to Bleeding</Disease_Detail>
      <Disease_DB>SSC032</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/susceptibility_to_bleeding_due_to_fluindione_treatment?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Glibenclamide Toxicity</Disease_Name>
      <Disease_Detail>Glibenclamide Toxicity</Disease_Detail>
      <Disease_DB>GLB018</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/glibenclamide_toxicity?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Carbutamide Toxicity</Disease_Name>
      <Disease_Detail>Carbutamide Toxicity</Disease_Detail>
      <Disease_DB>CRB146</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/carbutamide_toxicity?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Phenytoin Toxicity</Disease_Name>
      <Disease_Detail>Phenytoin Toxicity</Disease_Detail>
      <Disease_DB>PHN011</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/phenytoin_toxicity?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Susceptibility to Hypoglycemia Due to Glimepiride Treatment</Disease_Name>
      <Disease_Detail>Susceptibility to Hypoglycemia</Disease_Detail>
      <Disease_DB>SSC007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/susceptibility_to_hypoglycemia_due_to_glimepiride_treatment?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Phenprocoumon Toxicity</Disease_Name>
      <Disease_Detail>Phenprocoumon Toxicity</Disease_Detail>
      <Disease_DB>PHN010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/phenprocoumon_toxicity?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Tolbutamide Poor Metabolizer</Disease_Name>
      <Disease_Detail>Tolbutamide Poor Metabolizer</Disease_Detail>
      <Disease_DB>TLB001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/tolbutamide_poor_metabolizer?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Colon Adenoma</Disease_Name>
      <Disease_Detail>Colon Cancer</Disease_Detail>
      <Disease_DB>CLN044</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/colon_adenoma?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Warfarine Toxicity</Disease_Name>
      <Disease_Detail>Warfarine Toxicity</Disease_Detail>
      <Disease_DB>WRF004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/warfarine_toxicity?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Susceptibility to Hypoglycemia Due to Glipizide Treatment</Disease_Name>
      <Disease_Detail>Susceptibility to Hypoglycemia</Disease_Detail>
      <Disease_DB>SSC010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/susceptibility_to_hypoglycemia_due_to_glipizide_treatment?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Drug-Induced Hepatitis</Disease_Name>
      <Disease_Detail>Drug-Induced Hepatitis</Disease_Detail>
      <Disease_DB>DRG002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/drug_induced_hepatitis?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Susceptibility to Bleeding Due to Phenprocoumon Treatment</Disease_Name>
      <Disease_Detail>Susceptibility to Bleeding</Disease_Detail>
      <Disease_DB>SSC016</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/susceptibility_to_bleeding_due_to_phenprocoumon_treatment?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Susceptibility to Hypoglycemia Due to Carbutamide Treatment</Disease_Name>
      <Disease_Detail>Susceptibility to Hypoglycemia</Disease_Detail>
      <Disease_DB>SSC014</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/susceptibility_to_hypoglycemia_due_to_carbutamide_treatment?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Warfarin Sensitivity</Disease_Name>
      <Disease_Detail>Warfarin Sensitivity</Disease_Detail>
      <Disease_DB>WRF002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/warfarin_sensitivity?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Susceptibility to Hypoglycemia Due to Glibenclamide Treatment</Disease_Name>
      <Disease_Detail>Susceptibility to Hypoglycemia</Disease_Detail>
      <Disease_DB>SSC013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/susceptibility_to_hypoglycemia_due_to_glibenclamide_treatment?search=CYP2C9#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>STRUCTURE OF HUMAN CYTOCHROME P450 CYP2C9</PDB_Title>
      <PDB_ID>1OG2</PDB_ID>
      <Resolution>2.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1OG2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of human cytochrome P450 2C9 with bound warfarin.</PubMed_Title>
      <Author>Williams PA, et al.</Author>
      <Journal>Nature. 2003 Jul 24;424(6947):464-8.</Journal>
      <PubMed_ID>12861225</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of P4502C9 with Flurbiprofen bound</PDB_Title>
      <PDB_ID>1R9O</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1R9O</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution.</PubMed_Title>
      <Author>Wester MR, et al.</Author>
      <Journal>J Biol Chem. 2004 Aug 20;279(34):35630-7.</Journal>
      <PubMed_ID>15181000</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF HUMAN CYTOCHROME P450 CYP2C9</PDB_Title>
      <PDB_ID>1OG5</PDB_ID>
      <Resolution>2.55</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1OG5</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of human cytochrome P450 2C9 with bound warfarin.</PubMed_Title>
      <Author>Williams PA, et al.</Author>
      <Journal>Nature. 2003 Jul 24;424(6947):464-8.</Journal>
      <PubMed_ID>12861225</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04726</Pathway_ID>
      <Pathway_Title>Serotonergic synapse</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Nervous system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00980</Pathway_ID>
      <Pathway_Title>Metabolism of xenobiotics by cytochrome P450</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Xenobiotics biodegradation and metabolism</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00980</Pathway_ID>
      <Pathway_Title>Metabolism of xenobiotics by cytochrome P450</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Xenobiotics biodegradation and metabolism</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00591</Pathway_ID>
      <Pathway_Title>Linoleic acid metabolism</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Lipid metabolism</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00982</Pathway_ID>
      <Pathway_Title>Drug metabolism - cytochrome P450</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Xenobiotics biodegradation and metabolism</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00982</Pathway_ID>
      <Pathway_Title>Drug metabolism - cytochrome P450</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Xenobiotics biodegradation and metabolism</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00980</Pathway_ID>
      <Pathway_Title>Metabolism of xenobiotics by cytochrome P450</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Xenobiotics biodegradation and metabolism</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00982</Pathway_ID>
      <Pathway_Title>Drug metabolism - cytochrome P450</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Xenobiotics biodegradation and metabolism</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00982</Pathway_ID>
      <Pathway_Title>Drug metabolism - cytochrome P450</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Xenobiotics biodegradation and metabolism</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko00591</Pathway_ID>
      <Pathway_Title>Linoleic acid metabolism</Pathway_Title>
      <Pathway_Class>Metabolism</Pathway_Class>
      <Pathway_Subclass>Lipid metabolism</Pathway_Subclass>
    </Network>
  </Network_List>
  <Fold>
    <SCOP_Class>All alpha proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.b.cae.b.b.ca.html</SCOP_URL>
    <CATH_Class>Mainly alpha</CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1og2</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Detail>site,97,Arg;site,98,Gly;site,99,Ile;site,100,Phe;site,102,Leu;site,103,Ala;site,113,Val;site,114,Phe;site,217,Asn;site,364,Thr;site,365,Ser;site,366,Leu;site,367,Pro;site,476,Phe</Site_Detail>
      <Site_Reference>Williams P A, et al. Nature. 2003,424(6947):464-468.</Site_Reference>
      <Site_Type>Molecular rearrangement</Site_Type>
      <PubMed_ID>12861225</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>1.14.13.80@@1.14.13.48@@1.14.13.49</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC1/14/13/80.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD00820001</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-05-31</Create_Date>
</Organism_Record>